» Articles » PMID: 18612310

Caveolin 1 and Caveolin 2 Are Associated with Breast Cancer Basal-like and Triple-negative Immunophenotype

Overview
Journal Br J Cancer
Specialty Oncology
Date 2008 Jul 10
PMID 18612310
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Caveolin-1 (CAV1) and caveolin 2 (CAV2) are the principal structural proteins of caveolae, sphingolipid and cholesterol-rich invaginations of the plasma membrane involved in vesicular trafficking and signal transduction. Over the recent years there has been controversy about their role in breast cancer and their suitability as markers of basal-like phenotype. Caveolin-1 and CAV2 protein expression was assessed on a tissue microarray containing 880 unselected invasive breast cancer cases, by means of immunohistochemistry. Caveolin-1 and CAV2 expression was observed in 13.4 and 5.9% of all breast cancer, respectively. Their expression was strongly associated with high histological grade, lack of steroid hormone receptor positivity (ER and PR), and expression of basal markers (basal cytokeratins, P63, P-cadherin). Furthermore, there was a significant association between CAV1 and CAV2 expression and basal-like phenotype. On univariate analysis only CAV2 had a prognostic impact on breast cancer-specific survival; however, this was not independent from other traditional markers on multivariate analysis. Our results demonstrate that both CAV1 and CAV2 are associated with basal-like phenotype. Further studies are warranted to determine whether they play an oncogenic role in basal-like/triple-negative breast cancer development or are just surrogate markers for this subgroup.

Citing Articles

Location and Movement of the Oxytocin Receptor Differ Between the Normal and Diseased Prostate.

Gould M, Potapov D, Nicholson H Cancers (Basel). 2025; 17(2).

PMID: 39857963 PMC: 11763401. DOI: 10.3390/cancers17020182.


Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Teruel I, Castella E, Recalde S, Vinas G, Petit A, Trigueros M Int J Mol Sci. 2024; 25(22).

PMID: 39596307 PMC: 11594706. DOI: 10.3390/ijms252212241.


Expression Profiles of Dopamine-Related Genes and miRNAs Regulating Their Expression in Breast Cancer.

Sirek T, Sirek A, Borawski P, Rygula I, Krol-Jatrega K, Oplawski M Int J Mol Sci. 2024; 25(12).

PMID: 38928253 PMC: 11203454. DOI: 10.3390/ijms25126546.


Role of Caveolae family-related proteins in the development of breast cancer.

Han Q, Qiu S, Hu H, Li W, Li X Front Mol Biosci. 2023; 10:1242426.

PMID: 37828916 PMC: 10565104. DOI: 10.3389/fmolb.2023.1242426.


What is new in cancer-associated fibroblast biomarkers?.

Zhao Z, Li T, Yuan Y, Zhu Y Cell Commun Signal. 2023; 21(1):96.

PMID: 37143134 PMC: 10158035. DOI: 10.1186/s12964-023-01125-0.


References
1.
Abd El-Rehim D, Pinder S, Paish C, Bell J, Rampaul R, Blamey R . Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91(8):1532-42. PMC: 2410019. DOI: 10.1038/sj.bjc.6602184. View

2.
Barresi V, Cerasoli S, Paioli G, Vitarelli E, Giuffre G, Guiducci G . Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathol. 2006; 112(5):617-26. DOI: 10.1007/s00401-006-0097-1. View

3.
Bauer K, Brown M, Cress R, Parise C, Caggiano V . Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721-8. DOI: 10.1002/cncr.22618. View

4.
Savage K, Lambros M, Robertson D, Jones R, Jones C, Mackay A . Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007; 13(1):90-101. DOI: 10.1158/1078-0432.CCR-06-1371. View

5.
Savage K, Leung S, Todd S, Brown L, Jones R, Robertson D . Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2007; 110(2):245-56. DOI: 10.1007/s10549-007-9718-1. View